Contribution of both the sarcolemmal KATP and mitochondrial KATP channels to infarct size limitation by KATP channel openers: differences from preconditioning in the role of sarcolemmal KATP channels

被引:0
|
作者
Masaya Tanno
Tetsuji Miura
Akihito Tsuchida
Takayuki Miki
Yasuhiro Nishino
Yoshito Ohnuma
Kazuaki Shimamoto
机构
[1] Second Department of Internal Medicine,
[2] Sapporo Medical University School of Medicine,undefined
[3] South-1 West-16,undefined
[4] Chuo-ku,undefined
[5] Sapporo 060-8543,undefined
[6] Japan,undefined
关键词
KATP channel opener Myocardial infarction Mitochondrial KATP channel Sarcolemmal KATP channel Ischemic preconditioning Activation recovery interval;
D O I
暂无
中图分类号
学科分类号
摘要
The roles of sarcolemmal ATP-sensitive K+ (sarcKATP) and mitochondrial ATP-sensitive K+ (mitoKATP) channels in the cardioprotection induced by KATP channel openers remain unclear, though the mitoKATP channel has been proposed to be involved as a subcellular mediator in cardioprotection afforded by ischemic preconditioning (PC). In the present study, selective inhibitors of the sarcKATP and mitoKATP channels were used to examine the role of each channel subtype in infarct size limitation by KATP channel openers.
引用
收藏
页码:226 / 232
页数:6
相关论文
共 50 条
  • [1] Contribution of both the sarcolemmal KATP and mitochondrial KATP channels to infarct size limitation by KATP channel openers:: differences from preconditioning in the role of sarcolemmal KATP channels
    Tanno, M
    Miura, T
    Tsuchida, A
    Miki, T
    Nishino, Y
    Ohnuma, Y
    Shimamoto, K
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 364 (03) : 226 - 232
  • [2] Infarct size limitation by nicorandil:: Roles of mitochondrial KATP channels, sarcolemmal KATP channels, and protein kinase C
    Tsuchida, A
    Miura, T
    Tanno, M
    Sakamoto, J
    Miki, T
    Kuno, A
    Matsumoto, T
    Ohnuma, Y
    Ichikawa, Y
    Shimamoto, K
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (08) : 1523 - 1530
  • [3] Sarcolemmal and mitochondrial KATP channels and myocardial ischemic preconditioning
    Peart, JN
    Gross, GJ
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2002, 6 (04) : 453 - 464
  • [4] Role of mitochondrial and sarcolemmal KATP channels in ischemic preconditioning of the canine heart
    Sanada, S
    Kitakaze, M
    Asanuma, H
    Harada, K
    Ogita, H
    Node, K
    Takashima, S
    Sakata, Y
    Asakura, M
    Shinozaki, Y
    Mori, H
    Kuzuya, T
    Hori, M
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 280 (01): : H256 - H263
  • [5] Sarcolemmal KATP channels in ageing
    Jovanovic, S
    Jovanovic, A
    [J]. AGEING RESEARCH REVIEWS, 2004, 3 (02) : 199 - 214
  • [6] Regulation of cell survival by KATP channels:: Sarcolemmal, mitochondrial or both?
    Jovanovic, Aleksandar
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2006, 40 (06) : 964 - 964
  • [7] Infarct size limitation by bradykinin receptor activation is mediated by mitochondrial but not by sarcolemmal KATP channels in rabbit hearts
    Kita, H
    Miki, T
    Hasegawa, T
    Fukuma, T
    Miura, T
    [J]. CIRCULATION, 1999, 100 (18) : 630 - 630
  • [8] Infarct size limitation by bradykinin receptor activation is mediated by the mitochondrial but not by the sarcolemmal KATP channel
    Kita, H
    Miura, T
    Miki, T
    Genda, S
    Tanno, M
    Fukuma, T
    Shimamoto, K
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2000, 14 (05) : 497 - 502
  • [9] Infarct Size Limitation by Bradykinin Receptor Activation Is Mediated by the Mitochondrial But Not by the Sarcolemmal KATP Channel
    Hiroyuki Kita
    Tetsuji Miura
    Takayuki Miki
    Satoshi Genda
    Masaya Tanno
    Takayuki Fukuma
    Kazuaki Shimamoto
    [J]. Cardiovascular Drugs and Therapy, 2000, 14 : 497 - 502
  • [10] Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection
    Sato, T
    Costa, ADT
    Saito, T
    Ogura, T
    Ishida, H
    Garlid, KD
    Nakaya, H
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (01): : 182 - 188